Physician profile
Badar Hasan
NPI 1255710455
$4,895.28
in general payments reported to CMS, 2019-2025
14 companies · $1,997 in 2025
The $1,997 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,283 · 2020: $774 · 2021: $555 · 2024: $286 · 2025: $1,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,824 · Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,823.91 |
| Food and Beverage | $459.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,173.10 | 2019-2025 | Spyglass, General - Therapies |
| Janssen Biotech, INC. | $572.56 | 2019-2021 | |
| Abbvie INC. | $411.44 | 2019-2021 | |
| Gilead Sciences, INC. | $407.61 | 2019-2021 | |
| Olympus Corporation of The Americas | $366.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $298.62 | 2020-2021 | |
| Micro-Tech Endoscopy USA, INC. | $286.32 | 2024 | |
| Olympus America INC. | $87.02 | 2025 | Single Use Aspiration Needle Na-U200h, Endoclot Phs, Single Use Electrosurgical Knife Kd-655 |
| Merck Sharp & Dohme LLC | $83.59 | 2019 | |
| Intercept Pharmaceuticals, INC. | $71.98 | 2019-2021 | |
| Shire North American Group INC | $41.66 | 2019 | |
| Qol Medical, LLC | $41.28 | 2019 | |
| Cook Medical LLC | $28.57 | 2019 | |
| Celgene Corporation | $25.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Badar Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.